CURRICULUM VITAE Paul J. Hauptman, M.D.s3.amazonaws.com/.../CV_Paul_Hauptman_MD.pdf · CURRICULUM...

P.J. Hauptman April 2015 1

CURRICULUM VITAE

Paul J. Hauptman, M.D.

Office Address: Division of Cardiology

Saint Louis University Hospital, FDT-15 3635 Vista Avenue at Grand Boulevard St. Louis MO 63110 Telephone: 314-268-5293 Fax: 314-577-8861 E-mail: [email protected]

Personal Data: Place of Birth: New York, New York

Married: Debra I. Hauptman, MS, MSW Education: 1983 B.A. Columbia University

1987 M.D. Cornell University Medical College

Postdoctoral Training Internship and Residencies 1987-1988 Intern in Internal Medicine, Brigham and Women’s Hospital, Boston 1988-1990 Resident in Internal Medicine, Brigham and Women’s Hospital, Boston

Clinical and Research Fellowships 1987-1990 Clinical Fellow in Medicine, Harvard Medical School 1990-1992 Clinical Fellow in Cardiology, Mount Sinai Hospital, New York 1992-1993 Research/Clinical Fellow in Medicine, Cardiovascular Division, Brigham and Women’s Hospital, Boston and Research Fellow in Medicine,

Harvard Medical School Licensure and Certification

1989 Commonwealth of Massachusetts (71023), inactive 1990 New York State (182095), inactive 1990-2000 Diplomate, American Board of Internal Medicine (133833) 1993-2003 Diplomate, American Board of Internal Medicine, Cardiovascular Disease 1998 State of Missouri (MD 115045), active 2003-2013 Diplomate (ABIM Recertification), Cardiovascular Disease 2013-2023 Diplomate (ABIM Recertification), Cardiovascular Disease 2014-2024 Diplomate, (ABIM Certification), Advanced Heart Failure and Transplant

Cardiology Academic Appointments

1993-97 Instructor in Medicine, Harvard Medical School 1997-98 Assistant Professor of Medicine, Harvard Medical School 1998-2004 Associate Professor of Internal Medicine, Saint Louis University School

of Medicine


1998- 2007 Adjunct Associate Professor of Health Services Research, School of Public Health, Saint Louis University

2004-present Professor of Internal Medicine, Saint Louis University School of Medicine 2007-present Professor (secondary appointment), Health Management and Policy,

School of Public Health, Saint Louis University 2007 Visiting Professor, Institute of Medicine, Sahlgrenska Academy, Göteborg

University, Sweden (July-December) 2009-present Assistant Dean for Clinical Translational Research, Saint Louis University

School of Medicine Hospital Appointments

1993-98 Associate Physician, Brigham and Women's Hospital, Boston MA 1995-98 Attending Physician, Carney Hospital, Dorchester MA 1998-present Attending Physician and Director of Heart Failure and Transplantation,

Saint Louis University Hospital, St. Louis Missouri Other Appointments

2010-present Director, Clinical Trials Office, Saint Louis University School of Medicine Professional Development

2014 Participant, Executive Development Seminar for Interim and Aspiring Leaders, American Association of Medical Colleges, Washington DC

Awards and Honors

1983 Phi Beta Kappa 1985 CIBA Award for Outstanding Community Service 1987 Paul Sherlock Prize in Clinical Medicine and the Alfred M. Michaelis Prize

for Efficiency in Medicine, Cornell University Medical College 1987 Alpha Omega Alpha 1998 Award for Teaching Excellence, Carney Hospital 2006, 2011 Teacher of the Year Award, Division of Cardiology, Saint Louis University 2007 Caring Physician Award, Saint Louis University Hospital

Major Committee Assignments

Grant Review Committees 2001-02 Member, Grant Peer Review Committee (National), CV Pathophysiology,

American Heart Association 2001 Grant Reviewer (ad hoc), Health Services Research Dissemination

Implementation Study Section, Agency for Health Research and Quality (AHRQ)

2000-02 Member, Grant Review Committee, Great America Consortium Study Group, American Heart Association, M Creager MD, Chairman

2006 Grant Reviewer, RFA 05-003 Study Section: “Heart Failure Clinical Research Network”, National Heart Lung and Blood Institute (NHLBI); Scientific Review Administrator (SRA): Y Li-Smerin MD, PhD

2007 Grant Reviewer, RFA-HL-07-009 Study Section: “Ancillary Studies in Clinical Trials”, National Heart Lung and Blood Institute (NHLBI); SRA:


Y Li-Smerin MD, PhD 2009 Grant Reviewer, NHLBI Translational Research Implementation Program

(TRIP), Special Emphasis Panel, Research Infrastructure Grand Opportunities RFA-OD-09-004 Study section; SRA: Holly Krull, PhD.

2010 Grant Reviewer (ad hoc), Health Research Award Committee, Health Research Board (Dublin, Ireland). Chair T Maguire PhD

Clinical Trials and Registries 2003-06 Member, Clinical Events Committee, Phase III Mortality Trial of

Tolvaptan in Heart Failure: EVEREST. Sponsor: Otsuka Maryland Research Institute (OMRI), Bethesda MD

2005-07 Member, Steering Committee, Prospective Randomized Controlled Assessment of Once-Daily Controlled Release Coreg CR vs Twice-Daily Coreg IR on Measures of Compliance and Quality of Life in Patients with Heart Failure and Left Ventricular Systolic Dysfunction: CASPER. Sponsor: GlaxoSmithKline, Philadelphia PA

2006-2009 Member, Clinical Events Committee, Phase II Outcomes Trial of A1-Selective Adenosine Receptor Antagonist for Patients Hospitalized with Acute Heart Failure. PROTECT. Sponsor: NovaCardia, San Diego CA.

2008-2009 Member, Clinical Events Committee, International Multicenter Large Simple Trial to Evaluate the Long-Term Pulmonary and Cardiovascular Safety of Exubera in Patients with Diabetes Mellitus: VOLUME. Sponsor: Pfizer, New York, NY

2009-2010 Member, Clinical Events Committee, Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation. The BALANCE Study. Sponsor: Cardiokine Biopharma, Philadelphia PA

2010 Member, Clinical Events Committee, Evaluation of the HeartWare VAS for the Treatment of Advanced Heart Failure. Sponsor: HeartWare, Inc., Framingham MA

2010-present Member, Steering Committee, HN Registry: an observational prospective registry to identify demographic and clinical characteristics of patients hospitalized with euvolemic and hypervolemic hyponatremia and assess the comparative effectiveness of available treatments and the impact on resource utilization; Sponsor: Otsuka America Pharmaceutical, Rockville MD

2011-present Member, Steering Committee, INcrease Of Vagal TonE in Heart Failure (INOVATE-HF) Study; Sponsor: BioControl Medical, Yehud Israel

2012-present Member, Data Safety Monitoring Committee, “Randomized double blind placebo controlled study of the short term clinical effects of tolvaptan in patients hospitalized for worsening heart failure with challenging fluid management (SECRET of CHF Trial); Sponsor: Cardiovascular Clinical Science Foundation

2013-present Member, Clinical Events Committee, International Study of Comparative Health Effectiveness with Medical and Invasive Approaches: ISCHEMIA. Sponsor: NIH.

2014 Member, Clinical Events Committee, “Adipose-derived regenerative cells in the Treatment of patients with chronic Heart disease Not Amenable to


surgical or interventional revascularization- The ATHENA Clinical Trial. Sponsor: Cytori

Member, Clinical Events Committee, “AMR-001 Versus Placebo Post ST Segment Elevation Myocardial Infarction: PreSERVE-AMI Trial”. Sponsor: NeoStem

National Committees/Panels 2001-06 Member, Care Standards Committee, Heart Failure Society of America 2005-07 Consultant, Circulatory System Devices Panel of the Medical Devices

Advisory Committee, CDRH, Food and Drug Administration 2005-07 Member, Program Committee, 10th and 11th Annual Meetings, HFSA 2006-2009 Chairman, Quality of Care Committee (formerly: Care Standards), HFSA 2009-present Member (appointed), Education Committee, HFSA 2012 HFSA Representative, Technical Panel of the American College of

Cardiology: “Appropriate Use Criteria for Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy”

2013-14 Subcommittee on Continuing Medical Education, HFSA 2013 Member, NHLBI-ODS Working Group on “Designing Studies to Evaluate the Role of Nutrition and Diet in Heart Failure Management”.

2013-present Member, Group on Research Advancement and Development, American Association of Medical Colleges (AAMC)

2013-present Co-Chair, Cardiac Disease Palliation Working Group of the Geriatric Cardiology Section, American College of Cardiology

2013-present Member (appointed), Development Committee, HFSA 2014-present Member (appointed), Lifetime Achievement Award Committee, HFSA National Meetings 2001 Abstract Grader, 74th Annual Scientific Sessions-American Heart

Association (AHA) 2002 Abstract Grader, 75thAnnual Scientific Sessions- AHA 2003 Abstract Grader, 7th Annual Scientific Meeting-HFSA and 76th Annual

Scientific Sessions, AHA Heart Failure Society of America representative to the Program Committee,“End-of-Life Program 2004”, The Society of Geriatric Cardiology

2004 Abstract Grader, 77th Annual Scientific Sessions, AHA; 25th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation; 8th Annual Scientific Meeting of the HFSA; and 54th Annual Scientific Session, American College of Cardiology (ACC)

2005 Abstract Grader, 9thAnnual Scientific Meeting, HFSA 2006 Abstract Grader, 79th Annual Scientific Sessions-AHA, 10th Annual

Scientific Sessions of the HFSA and 56th Annual Sessions of the ACC 2007 Abstract Grader, 11th Annual Scientific Sessions of the HFSA 2008 Abstract Grader, 12th Annual Scientific Sessions of the HFSA; 81st Annual

Scientific Sessions of the AHA 2009 Abstract Grader, 13th Annual Scientific Sessions of the HFSA, 82nd

Annual Scientific Sessions of the AHA


2010 Abstract Grader, 14th Annual Scientific Sessions of the HFSA, 83rd Annual Scientific Sessions of the AHA

2011 Abstract Grader, 15th Annual Scientific Sessions of the HFSA 2012 Abstract Grader, 85th Annual Scientific Sessions of the AHA 2013 Abstract Grader, 86th Annual Scientific Sessions of the AHA 2014 Abstract Grader, 87th Annual Scientific Sessions of the AHA Regional: 1994 Chairman, Central Selection Committee, Boston Center for Heart

Transplantation 1995-96 Advisor, Committee on Congestive Heart Failure, Massachusetts Hospital-

Health Plan Information Partnership 1999 Alternate, UNOS Heart Region 8 Review Board 2001-02 Member, UNOS Heart Region 8 Review Board 2003-05 Board Member, American Heart Association, Heartland Affiliate/Greater

St. Louis Division 2004-05 Member (Appointed), Medical Affairs Executive Committee, Mid-

America Transplant Services, St. Louis Missouri 2009-2013 University Coordinator (Appointed), Regional Health Commission on

Community/University Health Research Partnerships (CUHRP), St. Louis 2014-present Saint Louis University representative to the Executive Committee of the

Institute for Clinical and Translational Science (Washington University) Saint Louis University Hospital: 1998-99 Transplant Global Billing Working Group 1999-2005 Pharmacy, Therapeutics, Nutrition and Transfusion Committee 2006 Physician Advisor: In-patient general cardiology; cardiac care units Saint Louis University School of Medicine: 1999-2007 Fellow Selection Committee, Division of Cardiology 2000-02 Resident Education Committee, Department of Medicine 2001-05 At-large Member (elected), Executive Committee of the Faculty Assembly 2004 Faculty Representative (appointed), Internal Analysis and Evaluation

Committee review of the Department of Surgery 2005-2011 Member (elected), Faculty Affairs Committee 2008-2011 Member, Dean’s Planning and Advisory Committee 2009-2010 Member, Search Committee, Division Director-Cardiology 2009-2010 Study Section Chair, President’s Research Fund Seed Grant Programs 2011 Member (ad hoc), Research Integrity Inquiry Committee 2010-12 Member, University Research Compliance Committee 2010-present Ex Officio Member, Research Planning Committee 2012-2013 Co-Chair, Task Force on Sustainability of Research 2012-2014 Member, Internal Grant Review Committee: Summer Research

Fellowship for Medical Students 2012-present Member, Internal Grant Review Committee: President’s Research Fund 2012-present Member, Conflict of Interest in Research Committee 2013 Member, Search Committee, Associate Chief of Service for Research,


John Cochran VA Medical Center (St. Louis) 2014-present Co-director, Medical Student Summer Research Fellowship Program Cornell University Medical College: 1984-1987 Professional Conduct Appeals Committee

Editorial Boards

2005-2008 Journal of the International Society of Heart and Lung Transplantation 2005-2011 Journal of Cardiac Failure 2012-2014 Cardiology News 2008-2011 Circulation: Heart Failure 2006-present Heart Failure Reviews

Editorial Positions 2007-2009 Associate Editor, European Journal of Heart Failure 2011-2014 Associate Editor, Circulation: Heart Failure 2015-present Editor-in-Chief, Journal of Cardiac Failure Editorships

2010 Guest Editor, “Vagus Nerve Stimulation in Heart Failure”, Heart Failure Reviews, Volume 16, Issue 2, February 2011

2012 Guest Editor, Archives of Internal Medicine Invited Journal Reviewer (alphabetical order):

American Heart Journal (year of most recent review: 2009) American Journal of Cardiology (2006) American Journal of Cardiovascular Drugs (2010) American Journal of Managed Care (2004) American Journal of Medicine (2004) Archives of Internal Medicine (2012) Catheterization and Cardiovascular Diagnosis (1999) Circulation (2008) Circulation: Cardiovascular Quality and Outcomes (2009) Circulation: Heart Failure (2013) Coronary Artery Disease (2002) European Journal of Heart Failure (2009) Expert Review of Cardiovascular Therapy (2007) Heart Failure Reviews (2014) Indian Journal of Medical Research (2007) International Journal for Quality in Health Care (2004) Journal of the American College of Cardiology (2012) Journal of the American Geriatrics Society (2008) Journal of the American Medical Association (2014) Journal of Cardiac Failure (2010) Journal of Gerontology: Medical Sciences (2004) Journal of the International Society of Heart and Lung Transplantation (2007) Journal of Pain and Symptom Management (2013)


Journal of Palliative Medicine (2006) New England Journal of Medicine (2013) Progress in Palliative Care (2008) The Lancet (2001) Transplantation (2005)

Peer Review Activities (non-grant, non-journal review): External Peer Reviewer, On behalf of the American Heart Association for the ACCF/AHA/ACP Task Force on Clinical Competence and Training: The ACCF/AHA/ACP/HFSA 2009 Clinical Competence Statement on Management of Patients with Advanced Heart Failure and Cardiac Transplantation (2008) External Peer Reviewer, "Systematic Review of Decision Tools and their Suitability for Patient-centered Decision-making regarding Electronic Cardiac Devices", produced by the Technology Assessment Program (TAP), Agency for Healthcare Research and Quality at the request of the Coverage and Analysis Group at the Centers for Medicare and Medicaid Services (2011) External Peer Reviewer, On behalf of the American Heart Association for the 2013 ACCF/AHA Guideline for the Management of Heart Failure. Circulation 2013;128:e240–e327. Technical Panelist, Representing the HFSA. Russo AM, Stainback RF, Bailey SR, Epstein AE, Heidenreich PA, Jessup M, Kapa S, Kremers MS, Lindsay BD, Stevenson LW. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography and Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol 2013;61:1323-73. doi:10.1016/j.jacc.2012.12.017

Memberships in Professional Societies

1994-08 Member, International Society of Heart and Lung Transplantation 1995-96 Member, Association for Health Services Research 1997-present Member, Heart Failure Society of America (inaugural year)

Research Interests:

1. Outcomes research in cardiovascular diseases 2. Physician decision-making in advanced heart failure 3. Clinical trials in congestive heart failure

Research Funding Information: Federal, Foundation or Institutional Grants 1993-1995 NIH: National Research Service Award:

Role of anti-endothelial cell antibodies in heart transplantation


($69,100) 1994 Investigator: The Consequences of Variation in the Treatment of

Acute Myocardial Infarction, AHCPR HS06341 (PI: Barbara McNeil, MD, PhD)

1995-97 Investigator: Improving Compliance with Acute MI Practice

Guidelines, AHCPR 07357-03 (PI: Steven Soumerai, PhD) 1994-98 Investigator: Validating Guidelines for the Care of AMI Patients, AHCPR HS08071 (PI: Barbara McNeil, MD, PhD) 1996-98 Charles King Trust Postdoctoral Fellowship-The Medical Foundation

($64,000)

1996-2000 Investigator: Quality of Care Measures for Cardiovascular Patients, AHCPR HS09487 (PI: Barbara McNeil, MD, PhD)

2002-2003 Grant-in-Aid, “Use of Inotropic Therapy in End-Stage Heart Failure”, American Heart Association Heartland Affiliate (direct $110,998, indirect $10,000), declined second year of support

2003-2007 RO1 AG021515, “Decision Making in End-Stage Heart Failure”, National Institute on Aging/NIH (direct $525,000; indirect $195,549) 2007 Visiting Professor Scholarship, The Wenner-Gren Foundation -

Stockholm Sweden (120,000SEK = $17,300 US) 2011-12 President’s Research Fund, “Collaborative Decision Making in

Cardiac Device Therapy”, Saint Louis University School of Medicine (direct: $24,780)

2012-18 Co-Investigator, Heart Failure Clinical Research Network, NHLBI

U10HL110309, 5% effort (PI: V. Davila Roman and D. Mann) Industry Grants (unrestricted) 2000-01 Educational grant: Development of protocols with intravenous beta

blockade in class IV heart failure patients (Sponsor: Baxter Pharmaceuticals; $25,000)

2006-07 Research grant: Economics of in-patient care for acute decompensated

heart failure (Sponsor: Orqis Medical; $60,000) Federally Sponsored Clinical Trials 2012-2014 Local Principal Investigator, Using Allopurinol to Relieve Symptoms

in Patients With Heart Failure and High Uric Acid Levels: EXACT-HF. ClinicalTrials.gov Identifier: NCT00987415 (Sponsor: Duke


University/NHLBI Heart Failure Network) 2013-present Local Principal Investigator, Functional Impact of GLP-1 for Heart

Failure Treatment: FIGHT. ClinicalTrials.gov Identifier: NCT01800968 (Sponsor: Duke University/NHLBI Heart Failure Network)

2015-present Local Principal Investigator, Oral Iron Repletion Effects On Oxygen

Uptake in Heart Failure: IRONOUT. ClinicalTrials.gov Identifier: NCT02188784 (Sponsor: Duke University/NHLBI Heart Failure Network)

Industry Sponsored Clinical Trials and Grants (initiation-end date) 1993-1995 Principal Investigator: Trial of Pentoxifylline to Prevent Renal Failure

in Cardiac Transplant Recipients on Cyclosporine (Investigator-initiated; Supported by: Hoechst-Roussel, Inc.)

1993-97 Local Principal Investigator: Randomized, Double-Blind Comparative

Trial of Mycophenolate Mofetil or Azathioprine each in combination with Cyclosporine and Corticosteroids for the Prevention of Rejection in Cardiac Allograft Recipients, (Sponsor: Roche BioScience; $534,705)

1996-98 Local Principal Investigator, Neoral versus SandImmune in Heart

Transplant Recipients. (Sponsor: Sandoz Pharmaceutical Corp; $94,763)

1998-99 Local Principal Investigator: Natrecor versus Dobutamine Therapy for

Symptomatic Decompensated CHF: A Safety Study using 24-hour Holter Monitoring: “PRECEDENT”. (Sponsor: Scios, Inc; $32,190)

Local Principal Investigator: Safety and efficacy study of intravenous administration of YM087. (Sponsor: Parke-Davis; $92,432)

Local Principal Investigator: Carvedilol Prospective Randomized Cumulative Survival trial, the “COPERNICUS” Trial. (Sponsor: Smith Kline Beecham; $6,067) Local Principal Investigator: Weight monitoring in Heart Failure (“WHARF”), a pilot randomized trial of the DayLink monitor to determine outpatient efficacy in patients with decompensated CHF. (Sponsor: Alere Medical Corp.; $9,600)

1998-07 Local Principal Investigator, Study of the Efficacy and Safety of SDZ

RAD versus Azathioprine as part of a Triple Immunosuppressive Therapy Regimen in de novo Heart Transplant Recipients. (Sponsor: Novartis Pharmaceutical Corporation; $238,591) and B254 Extension


Study (Novartis; $5050) 2000 Local Principal Investigator: A Phase II Multi-center, Randomized

Double-Blind Pilot Trial Evaluating the Effects of Infliximab (Remicade) in patients with class III and IV congestive heart failure The ATTACH Trial. (Sponsor: Centocor; $25,000)

Local Principal Investigator: Candesartan Cilexetil in Heart Failure:

Assessment of Reduction in Mortality and Morbidity. “CHARM” protocols (Sponsor: AstraZeneca; $7,000)

Local Principal Investigator: Study to Evaluate the Effects of Oral Administration of Tolvaptan (OPC-41061) when Compared to Furosemide and the Combination of Tolvaptan and Furosemide in Patients with CHF. The VICTOR Study. (Sponsor: Otsuka America Pharmaceutical, Inc; $126,000)

2001 Local Principal Investigator, Prospective Evaluation and Identification

of Cardiac Decompensation in Patients with Heart Failure by Impedance Cardiography Test. The PREDICT Study, (Sponsor: CardioDynamics Inc.; $11,502)

Local Principal Investigator, Study to Assess the Effect of Valsartan

on Heart Rate Variability in patients with chronic CHF. CVAL-489. (Sponsor: Novartis Pharmaceuticals Corp; $6,495).

Local Principal Investigator, Phase II, Double Blind Dose

Comparative Study of the Efficacy, Tolerability and Safety of MCC-135 in Patients with Chronic Congestive Heart Failure (Sponsor: Mitsubishi; $10,000).

2002 Local Principal Investigator, Cardiac Support Device Randomized

Trial (Sponsor: Acorn Cardiovascular; $174,270), active as Continued Access Protocol (“CAP”)

Local Principal Investigator, Randomized Evaluation of Intravenous

Levosimendan Efficacy versus Placebo in the Short Term Treatment of Decompensated Chronic Heart Failure- The REVIVE Study. ClinicalTrials.gov Identifier NCT00048425 (Sponsor: Orion, $120,000+).

Local Principal Investigator, Tolvaptan (OPC-41061) dose finding

study (Sponsor: Otsuka America Pharmaceutical, Inc; $32,500) Principal Investigator, Predicting Cardiac Events using B-type

Natriuretic Peptide, a Time-Insensitive Predictive Instrument and Visual Analog Scale in Patients with Congestive Heart Failure


(Investigator-initiated, Saint Louis University IRB# 12219), inactive

2003-7 Local Principal Investigator, Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan- The EVEREST Study. ClinicalTrials.gov Identifier NCT00071331 (Sponsor: Otsuka America Pharmaceutical, Inc., $115,600)

2004-6 Local Principal Investigator, Randomized Double Blind Study

Evaluating the Effects of Eplerenone on Ventricular Remodeling in Patients with LV Systolic Dysfunction and Mild to Moderate Heart Failure Remodeling Study-REMODEL. ClinicalTrials.gov Identifier NCT00082589 (Sponsor: Pfizer, $32,390)

2004-7 Local Principal Investigator, Multicenter Trial of the Orqis Medical

Cancion Therapy for the Enhanced Treatment of CHF Unresponsive to Medical Therapy-MOMENTUM. ClinicalTrials.gov Identifier NCT00357591 (Sponsor: Orqis Medical, $35,000+)

2005-6 Local Principal Investigator, Open Label Non Randomized

Comparison of the Pharmacokinetic Profiles of Carvedilol CR and IR on Repeat Dosing in Chronic CHF Patients and Survivors of AMI. Coreg SKF 105517-369 Study. ClinicalTrials.gov Identifier NCT00272805 (Sponsor: GSK; $34,763).

2006-9 Local Principal Investigator, Multicenter, Randomized Double-blind

Study of the effects of KW-3902 Injectable Emulsion on Heart Failure Signs and Symptoms and Renal Function in Patients with Acute Heart Failure and Renal Impairment who are Hospitalized for Volume Overload and Require Intravenous Diuretic Therapy-The PROTECT study. ClinicalTrials.gov Identifier NCT00354458 (Sponsor: NovaCardia, Inc; $90,000+)

2007-2010 Local Principal Investigator, Reduction of Events with Darbepoetin

alfa in Heart Failure Trial- RED-HF Trial. ClinicalTrials.gov Identifier NCT00358215 (Sponsor: Amgen; $9050)

2008-2010 Local Principal Investigator, The BALANCE Study: Treatment of

HyponatrEmia BAsed on LixivAptan in NYHA class III-IV Cardiac Patient Evaluation. ClinicalTrials.gov Identifier: NCT00578695 (Sponsor: Cardiokine: $8000)

2008-2010 Local Principal Investigator, Calcium Upregulation by Percutaneous

Administration of Gene Therapy in Cardiac Disease: CUPID. ClinicalTrials.gov Identifier: NCT00454818 (Sponsor: Celladon Corp: $76,564)

2011-2012 Co-Investigator, Clinical Research Grant, “Prognostic Utility of 123I-


mIBG and Established Heart Failure Risk Models,” (Sponsor: GE Healthcare: $30,000)

2012-2014 Local Principal Investigator, Xanthine Oxidase Inhibition for

Hyperuricemic Heart Failure Patients: EXACT. ClinicalTrials.gov Identifier: NCT00987415 (Sponsor: NHLBI: Heart Failure Network; Active, $20,000+)

2012-2015 Local Principal Investigator, Calcium Up-Regulation by Percutaneous

Administration of Gene Therapy In Cardiac Disease Phase 2b: CUPID Phase 2b Trial. ClinicalTrials.gov Identifier: NCT01643330 (Sponsor: Celladon Corp: Active, $110,000+)

2013-2015 Local Principal Investigator, Functional Impact of GLP-1 for Heart

Failure Treatment: FIGHT. ClinicalTrials.gov Identifier: NCT01800968 (Sponsor: NHLBI: Heart Failure Network; Active)

2015-present Local Principal Investigator, Study of High-dose Spironolactone vs.

Placebo Therapy in Acute Heart Failure: ATHENA-HF. ClinicalTrials.gov Identifier: NCT02235077. (Sponsor: NHLBI: Heart Failure Network; Active)

2015-present Local Principal Investigator, Study Examining the Prevalence of TTR

Mutations in Subjects Suspected of Having Cardiac Amyloidosis: DISCOVERY. ClinicalTrials.gov Identifier: NCT02252653 (Sponsor: Alnylam)

2015-present Local Principal Investigator, ClinicalTrials.gov Identifier: Phase 3

Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin-Mediated Familial Amyloidotic Cardiomyopathy. ClinicalTrials.gov Identifier: NCT02319005 (Sponsor: Alnylam)

Self Report of Teaching:

Harvard Medical School 1994, 1995 Section Leader, cardiovascular pathophysiology for 2nd year students Saint Louis University School of Medicine 1998-present Cardiovascular fellowship and Internal Medicine housestaff lectures 1998-2008 Heart Failure and Transplantation Program- academic program

development for 1st and 2nd year cardiology fellows: design and update of educational syllabus; monthly teaching sessions for fellows

1998-2003 Faculty, Annual Internal Medicine Board Review course 2000-2006 Participating Faculty, Internal Medicine Resident morning report 2000 Research Advisor, Internal Medicine Residency Program: Samer

Alkaade, MD: “Quality of Life Measurement in Heart Failure Trials” 2001 Research Advisor, Internal Medicine Residency Program: Olaf Hedrich,

MD: “Evaluation of Resource Utilization in a Heart Failure Disease


Management Program” 2001, 2003 Faculty, Death and Dying unit, 2nd year medical students: “Patient,

Physician and Society” course 2003-04 Mentor for Senior Medical Resident theses: A Doshi MD (“Allograft

Vasculopathy”), B Czarnick MD (“Diastolic HF”), S Kuehn MD (“Diagnostic Techniques in HF”); S Abbas MD (“Physiology of the Transplanted Heart”)

2006 Faculty, Cardiovascular Physiology section for 2nd year medical students 2005-present Faculty Judge, Annual AOA Medical Student Research Forum

2010-2012 Faculty Mentor, Department of Medicine Mentoring Program 2012-present Preceptor, Internal Medicine, Year 3 Medical Students 2013 Faculty Judge, GME Research Poster Competition

2013-present Faculty Mentor, Wilson King MD, Division of Cardiology, Department of Pediatrics, Cardinal Glennon Children’s Hospital

Saint Louis University School of Public Health

2009 Faculty, “Introduction to Medicine” course for MPH/PhD candidates 2009 Dissertation Committee Member, Jason Swindle MPH, PhD candidate in

Public Health Studies (health services research): “Relating resource utilization and outcomes among a heterogeneous heart failure population”

2011 Dissertation Committee Member, Lauren Garfield MPH, PhD candidate in Public Health Studies (health services research): “Depression pharmacotherapy, comorbid anxiety and the incidence of cardiovascular outcomes in a VA population”

2012-2015 Dissertation Committee Member, Jiajing Chen MPH, PhD candidate in Public Health Studies: “Risks and benefits associated with exenatide in type 2 diabetes: clinical and economic implications”

2014-2015 Dissertation Committee Member, Caress Dean MPH, PhD candidate: “Physician’s use of the AHA Guidelines as a guide to preventing cardiovascular disease”

Invited CME Presentations and Course Directorships (selected): 1993 Thoracic Organ Transplantation course, Minneapolis Heart Institute,

Tucson, AZ. “Endovascular Biology”. 1994 Cardiology Grand Rounds, University of Pisa, Italy. “Graft

Arteriosclerosis: Issues and Controversies”. 1995 Second Symposium on Cardiac Allograft Vasculopathy, St. Louis MO.

“Non-immune Risk Factors for Allograft Coronary Artery Disease”. 1996 Cardiology Grand Rounds, University of Massachusetts Medical Center, Worcester MA. “Heart Transplantation: The Beginning and the End”.

Cardiology Grand Rounds, Good Samaritan Medical Center, Brockton MA and Maine Medical Center, Portland ME. “Long term Complications of Heart Transplantation”.

1997 Presenter, UNOS Thoracic Organ Committee national meeting, Kansas City MO. “The New England Organ Bank Variance: Insights into National Heart Allocation”.

1998 Medical Grand Rounds, Carney Hospital, Dorchester MA. “Update on


Congestive Heart Failure” and “Health Services Research in Cardiovascular Diseases”

Transplant Grand Rounds, Allegheny General Hospital, Pittsburgh PA. “Acute Rejection and other Complications of Heart Transplantation”. Medical Ground Rounds, Saint Louis University Health Sciences Center. “Update in the Management of Congestive Heart Failure, 1998” Course Director, Continuing Medical Education program, “Therapeutic Advances in Congestive Heart Failure Management”, Saint Louis University School of Medicine

1999 Course Director, Continuing Medical Education breakfast series (5) for physicians, Saint Louis University School of Medicine

Faculty participant, annual meeting of the American College of Physicians-Missouri chapter, Osage MO. “Congestive Heart Failure: Management Update”

2000 Faculty, 10th Annual Symposium, Advances in Medicine, Kneibert Clinic, Poplar Bluffs, MO. “Essential Hypertension: Clinical Overview”

Course Co-Director, Continuing Medical Education program, “Cardiology for the Primary Care Physician in the New Millennium”, Saint Louis University School of Medicine.

2001 Visiting Professor, Cardiology Grand Rounds, University of Arkansas for Medical Sciences, Little Rock, AR. “Measuring Health-Related Quality of Life and Other Challenges in Heart Failure Trials”.

Visiting Professor, Medical College of Virginia, Richmond, VA. “Transplantation and Immunosuppression: Overview and Update”

Cardiology Grand Rounds, Albert Einstein Hospital, Philadelphia PA. “Beta-Blockade in Heart Failure: Insights and Commentary on Challenges for Clinical Trial Design”

2002 Cardiology Grand Rounds, New York Hospital/Cornell, Mount Sinai Medical Center (New York), University of Chicago and Temple University. “Measuring Health-Related Quality of Life and Other Challenges in Heart Failure Trials”

Faculty presenter, “Measurement of Outcomes in Advanced Heart Failure and Evaluation of Approaches to Care”, Consensus Conference on Supportive and Palliative Care for Advanced Heart Failure, Salt Lake City

2003 Cardiology Grand Rounds, University of Illinois, Chicago, January. “Measuring Health Related Quality of Life in Heart Failure Trials”

Faculty presenter, “Defining the Patient for Palliative Care: The HFSA Position”, Second Consensus Conference on Supportive and Palliative Care for Advanced Heart Failure, Salt Lake City

Faculty presenter, “Will Laboratory Examination Supplant the Physical for Diagnosis and Follow-up of Heart Failure” and “Overcoming Barriers to Treatment by the Guidelines”, 14th Annual Symposium of the Management of Cardiovascular Disease, University of Kansas School of Medicine, Wichita KS

Faculty presenter, “Congestive Heart Failure”, 1st Annual Northeast Kansas Primary Care Physician Conference, Kansas City KS


Cardiology Grand Rounds, Henry Ford Hospital, Detroit MI. “Measurement of Endpoints in Heart Failure Trials: Jousting at Windmills?”

2004 Visiting Professor, Cardiology Grand Rounds, Tufts-New England Medical Center, Boston MA. “Living and Dying with Heart Failure: A Treatise on What We Know and What We Don’t Know”.

Faculty, Updates in Cardiology sponsored by Saint Louis University. “New Approaches to Decompensated Heart Failure”

Cardiology Grand Rounds, Ochsner Clinic, New Orleans LA. “Living and Dying with Heart Failure”.

Cardiology Grand Rounds, Krannert Heart Institute, Indianapolis IN. “Evidence Based Approaches to Reducing the Risk of CV Events”

2005 Cardiology Grand Rounds, Baystate Medical Center, Springfield MA and the University of Maryland, Baltimore MD. “Living with End-Stage Heart Failure”

2006 Faculty, Symposium: “Key Topics in Current Cardiovascular Clinical Research”, sponsored by Cardiovascular Clinical Studies: “Efficacy to Effectiveness in Drug Therapy”, Atlanta

Faculty, Symposium, Clinical Concepts in Heart Failure, Midwest Heart Foundation, Lake Geneva WI. “End of Life Issues in Heart Failure Care”

2007 Faculty, Kynett Symposium, Jefferson Medical College, Philadelphia PA. “Palliative Care in Heart Failure: An Unmet Need”

Cardiology Grand Rounds, Jefferson Medical College, Philadelphia PA. “Drugs versus Devices in Advanced Heart Failure”

Faculty, Ponte Vedra Cardiovascular Symposium, Ponte Vedra FL. “Pathophysiology of Heart Failure”

2008 Cardiology Grand Rounds, University of Colorado Health Sciences Center, Denver CO, Henry Ford Hospital-Detroit and University of Missouri,

Kansas City. “Implantable Devices in Advanced Heart Failure: Difficult Decisions, Difficult Discussions”

Faculty, 7th Annual Primary Care Conference of the HFSA: “What to Do and When: Managing Heart Failure in 2008”

2009 Medical Grand Rounds, Saint Louis University School of Medicine and Cardiology Grand Rounds, Washington University School of Medicine: “Implantable Devices in Advanced Heart Failure: Difficult Decisions, Difficult Discussions”

Faculty, 2009 Forum on Heart Failure, Spectrum Health and Henry Ford Health Care System, Traverse City MI. “ACE inhibitors and Beta Blockers: What you may not know”

2010 Medical Grand Rounds, St. Anthony’s Medical Center, St. Louis MO. “Device therapy in Advanced Heart Failure”

Anandi L. Sharma Visiting Professorship and the Simon Dack MD Memorial Lecture. Mount Sinai Hospital, New York: “Implantable Devices in Advanced Heart Failure”.

2011 Cardiology Grand Rounds, Case Western, New York University and Tulane University Medical Centers. “Device Therapy in Advanced


Heart Failure: Too Much Too Late?” Faculty, Heart Failure Management-2011, Sponsor: University of North

Carolina. “Optimizing Patient Selection for Device Therapy- Focus on the Elderly”

2012 Visiting Professor, Division of Cardiovascular Medicine, Vanderbilt University; lecture “Palliative Care in Heart Failure”

Faculty, Ponte Vedra Cardiovascular Symposium-2012, Ponte Vedra FL. “Advanced Heart Failure in the Elderly”

Faculty, Seminar Series, Office for Faculty Affairs and Professional Development (SLU); “How to be a Clinical Trialist”

Faculty, Medscape CME programs, “Digoxin Toxicity: Awareness, Recognition and Treatment” and “The Different Faces of Hyponatremia”

2013 17th Annual William S. Pierce Lecture, Penn State University Heart and Vascular Institute, Milton S. Hershey Medical Center: “Palliative Care in Heart Failure”

Medicine Grand Rounds, Vista Medical Center, Waukegan IL: “Hyponatremia in Heart Failure”

Cardiology Grand Rounds, University of Utah Health Sciences Center: “The Heart Failure Readmissions Obsession”

Heart Failure Symposium, Prairie Heart Institute, Springfield IL: “Heart Failure Quality Care in an Era of Diminishing Resources”

Faculty, Medscape CME program, “Addressing the Risk for Sudden Cardiac Death in Heart Failure”

2014 Faculty, Heart Failure Management Symposium: Personalized Medicine to Optimize Care, U of Florida. “Managing Hyponatremia in Heart Failure”

Faculty, Medscape CME programs, “The Newly Diagnosed Ischemic Heart Failure Patient”, “Navigating the Treatment Algorithm for Heart Failure” and “Using a Team-based Approach to Biomarker-guided Therapy in Heart Failure”

2015 Cardiology Grand Rounds, Case Western Reserve-University Hospitals: “Prognostication in Heart Failure”

International / National Meetings

Panelist, Fireside Chat, 48th annual Scientific Sessions of the American College of Cardiology, “Advances in Heart Transplantation”, New Orleans LA. March 1999.

Chair, How-to Seminar: “How to Manage Long-Term Survivors of Heart Transplantation”. 73rd Scientific Session of the American Heart Association, New Orleans, November 2000.

Moderator, Abstract Presentations: Neurohormonal Modulation in Heart Failure. 73rd Scientific Session of the American Heart Association, New Orleans, Nov 2000.

Faculty Participant, Symposium: Update on Cardiac Transplantation. 50th Scientific Sessions of the American College of Cardiology, “Are Defibrillators and Left Ventricular Assist Devices the New Tools of the Trade?” Orlando FL, March 2001

Moderator, Cardiovascular Seminar: Functional Mechanisms in Clinical Heart Failure. 74th Scientific Session of the American Heart Association, Anaheim CA,


Nov 2001. Moderator, Abstract Presentations: Non-Pharmacologic Approaches to Treatment of

Heart Failure. 74th Scientific Session of the American Heart Association, Anaheim CA, November 2001.

Faculty Facilitator, Featured Poster Session, 6th Annual Heart Failure Society of America meeting, Boca Raton FL, September 2002

Moderator, Abstract Presentations: Understanding Outcomes in Heart Failure. 75th Scientific Session of the American Heart Association, Chicago IL, November 2002

Moderator, How-to Seminar: How to Manage the Patient with a Heart Transplant and Abstract Presentations: Evolving Concepts in the Management of Severe and Acute Heart Failure. 76th Scientific Session of the American Heart Association, Orlando FL, November 2003

Faculty and Featured Presenter, Debate Protagonist: Is end-of-life care an appropriate component of management of most elderly patients with chronic severe heart failure and who should do it- the cardiologist or the geriatrician? Annual Session of the American Society of Geriatric Cardiology, New Orleans LA March 2004.

Panelist, Key Issues in Trial Design for Devices in Heart Failure, Sponsor: Heart Failure Society of America, Washington DC, April 1-2, 2004

Moderator, How To Session: How to Manage the Elderly Patient with Heart Failure, 8th Annual Scientific Meeting, Heart Failure Society of America, Toronto, Sept 2004.

Panelist, Lunchtime Panel, Who is an Appropriate Candidate for Destination Left Ventricular Device Therapy? 54th Scientific Sessions of the American College of Cardiology, Orlando FL March 2005

Moderator, Symposia, (1) Addressing Health Disparities in Heart Failure and (2) Improving Quality of Life Through Symptom Management. 9th Annual Scientific Meeting, Heart Failure Society of America, Boca Raton, September 2005

Co-Chair, Meet the Experts, Issues in Palliative Care of Heart Disease, 55th Scientific Sessions of the American College of Cardiology, Atlanta GA, March 2006

Moderator, Panel Discussion, “Are We Focusing on the Right Things?” 1st Meeting on Ethical Issues in Care for Persons with Advanced Heart Failure (PC-HEART), Washington DC, April 18, 2006

Faculty, Debate Antagonist, “Heart Failure Fellowships Should Include Training in Device Implantation”, 27th Annual Scientific Session of the Heart Rhythm Society, Boston MA, May 2006

Moderator, Symposium, “The Economic Burden of Treating the Sickest of the Sick”, Tenth Annual Scientific Meeting, Heart Failure Society of America, Seattle, September 2006

Panelist, Cardiovascular Seminar, “When enough is enough: hospice” and Invited Oral Presentation “Determining prognosis in patients with heart failure”, 79th Scientific Session of the American Heart Association, Chicago IL Nov 2006

Panelist, Symposium, “Arrhythmia devices in advanced disease: difficult decisions and discussions with patients”, 11th Annual Scientific Meeting, HFSA, Washington DC, September 2007

Moderator, “Autoimmunity in Cardiomyopathy and Heart Failure: from patients to molecules and back to patients” First Annual International conference, sponsor: Swedish Research Council, Göteborg Sweden, November 2007


Moderator, “Difficult Decisions in End Stage Heart Failure”, 57th Scientific Sessions of the American College of Cardiology, Chicago IL, Mar 2008

Moderator/Panelist, “How to Facilitate Patient-Provider Communication in Heart Failure”, Twelfth Annual Scientific Meeting, HFSA, Toronto Sept 2008

Moderator, “Who Should Manage End-of-Life Care”?; Poster Discussant, “Cardiac Transplantation/Assist Devices--Basic and Clinical; Myocardial Function/Heart Failure”, 58th Annual Scientific Session of the American College of Cardiology, Orlando FL, Mar 2009

Panelist, How-To Session, “How To Conduct Disease Management in the Outpatient Setting”, 13th Annual Scientific Meeting, HFSA, Boston, September 2009

Moderator, “Heart Failure Outcomes in Community Settings”. Scientific Session of the American Heart Association, Orlando FL, Nov 2009

Panelist, “Cardiac Resynchronization Therapy in Advanced Heart Failure: Too Late?” and Discussant, “Risk Stratification in Heart Failure”, 59th Annual Scientific Session of the American College of Cardiology, Atlanta, Mar 2010

Faculty/Presenter, “Unresolved Issues and Future Directions with Diastolic Heart Failure”, XXth World Congress of the International Society for Heart Research, Kyoto Japan, May 2010

Lecturer, “Device Therapy in Advanced Heart Failure” and “New Strategy of Treatment for Heart Failure”, 14th Annual Scientific Meeting of the Japanese Heart Failure Society, Tokyo Japan, October 2010

Panelist, “Decision-Making along the Continuum of Care for Heart Failure”, 60th Annual Scientific Session of the ACC, New Orleans, March 2011

Faculty/Presenter, “How to Integrate Monitoring by Implantable Sensors into Routine Clinical Workflow” and Moderator, “Surgery and device intervention for the elderly with heart failure: assessing the need”, 2011 Congress of the Heart Failure Association of the European Society of Cardiology, Göteborg Sweden, May 2011

Faculty, Implantable Defibrillation Devices Symposium: “Preparing for Death with a Device”, 15th annual meeting of the HFSA, Boston MA September 2011

Moderator, Poster Session, “Long-term Issues in Heart Transplantation”, 61st Annual Scientific Session of the ACC, Chicago, March 2012

Faculty/Presenter, “Consequences of Poor Adherence”, 16th annual meeting of the HFSA, Seattle, WA September 2012

Faculty, Symposium “Patient-Centered Care in Heart Failure” and Panelist, Meet the Experts “Advanced Heart Failure in the Older Patient: Transplant versus DT versus Neither”, ACC.13, March 2013

Faculty/Moderator: Rapid Fire Abstract and Hyde Park Presentations, 17th annual meeting of the HFSA, Orlando FL September 2013

Moderator and Presenter, “Neuromodulation Trials: Time to Move from Proof of Concept to Outcome Trials”, 10th Global CardioVascular Clinical Trials Forum, Paris FR, December 2013.

Faculty, 62nd Annual Conference of the Israel Heart Society, and lecture “The Hospital Readmission Obsession”, Tel Aviv Israel

Competitive Submissions: Featured Presentations Hyde Park Plenary sessions of the Heart Failure Society of America:

“Quality of Life should not be Measured in Heart Failure Trials”, 4th annual scientific


meeting, Boca Raton, September 2000 “Leader pricing: Why Sam Walton would save the day”, 6th annual scientific meeting,

Boca Raton, September 2002 “United States Presidents and Cardiovascular Disease: What Bush, Nader and Kerry

Should Know”, 8th annual scientific meeting, Toronto Canada, September 2004 “Texas No-Limit Hold ‘Em: Dealing with Patient Preferences and Uncertainty”. 10th

annual scientific meeting, Seattle, September 2006 “As if Global Warming Were Not Enough: How Patients are Wrecking Clinical Trials in Heart Failure by Making Too Much Noise”. 13th annual scientific meeting, Boston, September 2009

BIBLIOGRAPHY Original Reports 1. Liscum L, Hauptman PJ, Hood DC, Holtzman E. Effects of barium and

tetraethylammonium on membrane circulation in frog retinal photoreceptors. Journal of Cell Biology 1982;95:296-309.

2. Cox CS, Hauptman PJ, Turro NJ. Dialkylaminobenzonitriles as fluorescence polarity

probes for aqueous solutions of cyclodextrins. Photochemistry and Photobiology 1984;39:597-601.

3. Merino A, Hauptman PJ, Badimon L, Badimon JJ, Cohen M, Fuster V, Goldman ME.

Echocardiographic "smoke" is produced by an interaction of erythrocytes and plasma proteins modulated by shear forces. J Am Coll Cardiol 1992;20:1661-8.

4. Hauptman PJ, Aranki S, Mudge GH, Couper GS, Loh E. Early cardiac allograft failure

following orthotopic heart transplantation. Am Heart J 1994;127:179-186. 5. Hauptman PJ, Couper GS, Aranki SF, Kartashov A, Mudge GH, Loh E. Pericardial

effusions following cardiac transplantation. J Am Coll Cardiol 1994;23:1625-29. 6. Winters GL, Hauptman PJ, Jarcho JA, Schoen FJ. Immediate evaluation of

endomyocardial biopsies for clinically suspected rejection after heart transplantation. Circulation 1994; 89:2079-84.

7. Ayanian J, Hauptman PJ, Guadagnoli E, Antman EM, Pashos CL, McNeil BJ. Belief and

practices of generalist and specialist physicians regarding drug therapy for acute myocardial infarction. N Eng J Med 1994;331:1136-42.

8. DeCaterina R, Tanaka H, Nakagawa T, Hauptman PJ, Libby P. The direct effect of

injectable cyclosporine and its vehicle cremophor on endothelial VCAM-1 expression. Transplantation 1995;60:270-75.

9. Hauptman PJ, Kartashov AI, Couper GS, Mudge GH, Aranki SF, Cohn LH, Adams DH.

Changing patterns in donor and recipient risk: a ten year evolution in one heart transplant center. J Heart Lung Transplant 1995;14:654-58.


10. Guadagnoli E, Hauptman PJ, Ayanian JZ, Pashos CL, McNeil BJ, Cleary PD. Variation in the use of cardiac procedures following acute myocardial infarction: a comparison of practice in two states. N Eng J Med 1995;333:573-78.

11. Hauptman PJ, Davis S, Miller L, Yeung AC. The role of non-immune risk factors in the

development and progression of graft arteriosclerosis: preliminary insights from a multi center intravascular ultrasound study. J Heart Lung Transplant 1995;14(part 2):S238-S242.

12. Yeung AC, Davis S, Hauptman PJ, Kobashigawa J, Miller L, Valantine H, Ventura H,

Wiedermann J, Wilensky R. Incidence and progression of transplant coronary artery disease over one year: results of a multi center trial using intravascular ultrasound. J Heart Lung Transplant 1995;14(part 2):S215-S220.

13. Kobashigawa J, Miller L, Yeung A, Hauptman PJ, Ventura H, Wilensky R, Valantine H,

Wiedermann J. Does acute rejection correlate with the development of transplant coronary disease? A multi center study using intravascular ultrasound. J Heart Lung Transplant 1995;14(part 2):S221-S226.

14. Miller L, Kobashigawa J, Valantine H, Ventura H, Hauptman PJ, ODonnell J,

Wiedermann J, Yeung A. The impact of cyclosporine dose and level on the development and progression of allograft coronary disease. J Heart Lung Transplant 1995;14(part 2):S227-S234.

15. McLaughlin TJ, Soumerai SB, Willison DJ, Gurwitz JH, Borbas C, Guadagnoli E,

McLaughlin B, Morris N, Cheng SC, Hauptman PJ, Antman E, Casey L, Asinger R, Gobel F. Adherence to national consensus guidelines for drug treatment of suspected acute myocardial infarction in community hospitals: evidence for undertreatment in women and the elderly. Arch Int Med 1996;156:799-805.

16. Weinfeld M, Piana R, Kartashov A, Hauptman PJ. Bradycardia: a late complication

following cardiac transplantation. Am J Cardiol 1996;78:969-71. 17. Gurwitz JH, McLaughlin TJ, Willison DJ, Guadagnoli E, Hauptman PJ, Gao X, Soumerai

S. Delayed hospital presentation in patients who have had acute myocardial infarction. Ann Intern Med 1997;126:593-599.

18. Willison D, Soumerai S, McLaughlin T, Gurwitz J, Gao X, Guadagnoli E, Pearson S,

Hauptman PJ, McLaughlin B. Consultations between cardiologists and generalists in the management of acute myocardial infarction. Arch Int Med 1998;158:1778-1783.

19. Soumerai SB, McLaughlin T, Gurwitz JH, Guadagnoli E, Hauptman PJ, Borbas C, Morris

N, McLaughlin B, Gao X, Willison DJ, Asinger R, Gobel F. Effect of local medical opinion leaders on quality of care for acute myocardial infarction: a randomized controlled trial. JAMA 1998;279:1358-63.

20. Shapiro CL, Hardenbergh PH, Gelman R, Blanks D, Hauptman PJ, Recht A, Hayes DF,

Harris J, Henderson IC. Cardiac effects of adjuvant doxorubicin and radiation therapy in


breast cancer patients. J Clin Oncol 1998;16:3493-501. 21. Eisen HJ, Hobbs RE, Davis SF, Laufer G, Mancini D, Renlund DG, Valantine H, Ventura

H, Vachiery JL, Bourge RC, Canver CC, Carrier M, Costanzo M-R, Copeland J, Dureau G, Frazier OH, Dorent R, Hauptman PJ, Kells C, Masters R, Michaud J-L, Paradis I, Smith A, Vanhaecke J, Feutren G, Turkin D, Mellein B, Mueller EA. Safety, tolerability and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized multicenter double-blind comparison with the oil-based formulation of cyclosporine. Results at six months after transplantation. Transplantation 1999;68:663-71.

22. Eisen HJ, Hobbs RE, Davis SF, Carrier M, Mancini DM, Smith A, Valantine H, Ventura H,

Mehra M, Vachiery JL, Rayburn BK, Canver CC, Laufer G, Costanzo M, Copeland J, Dureau G, Frazier OH, Dorent R, Hauptman PJ, Kells C et al. Safety, tolerability and efficacy of cyclosporine microemulsion in heart transplantation- results at 24 months after transplantation. Transplantation 2001;71:70-8.

23. Hauptman PJ, O’Connor KJ, Wolf RE, McNeil BJ. Angiography of potential cardiac

donors. J Am Coll Cardiol 2001;37:1252-8. 24. Guadagnoli E, Landrum MB, Normand SL, Ayanian JZ, Garg P, Hauptman PJ, Ryan TJ,

McNeil BJ. Impact of underuse, overuse and discretionary use on geographic variation in the use of coronary angiography following acute myocardial infarction. Medical Care 2001;39:446-58.

25. DiSalvo TG, Normand S-LT, Hauptman PJ, Guadagnoli E, Palmer HR, McNeil BJ.

Pitfalls in assessing the quality of care for patients with cardiovascular disease. Am J Med 2001;111:297-303.

26. Garg PP, Landrum MB, Normand SL, Ayanian JZ, Hauptman PJ, Ryan TJ, McNeil BJ,

Guadagnoli E. Understanding individual and small area variation in the underuse of coronary angiography following acute myocardial infarction. Medical Care 2002;40:614-26.

27. Hauptman PJ, Woods D, Pritzker M. Novel use of a short-acting intravenous beta-blocker

in combination with inotropic therapy as a bridge to chronic oral beta blockade. Clin Cardiology 2002;25:247-49.

28. Betkowski AS, Graff R, Chen JJ, Hauptman PJ. Panel reactive screening practices prior to

heart transplantation. J Heart Lung Transplant 2002:21:644-50. 29. Kirklin JK, Naftel DC, Bourge RC, McGiffin DC, Hill JA, Rodeheffer RJ, Jaski BE,

Hauptman PJ, Weston M, White-Williams C. Evolving trends in risk profiles and causes of death after heart transplantation: A ten-year multi-institutional study. J Thor Cardiovasc Surg 2003;125:881-90.

30. Starling RC, Hare JM, Hauptman PJ, McCurry KR, Mayer HW, Kovarik JM, Schmidli H.

Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. Am J Transplant 2004;4:2126-31.


31. Doshi AA, Rogers J, Kern MJ, Hauptman PJ. Effectiveness of percutaneous coronary

intervention in cardiac allograft vasculopathy. Am J Cardiol 2004;93:90-92. 32. Hauptman PJ, Masoudi F, Weintraub W, Pina I, Jones P, Spertus J. Variability in the

clinical status of patients with advanced heart failure. J Cardiac Fail 2004;10:397-402. 33. Derfler MC, Jacob M, Wolf RE, Bleyer F, Hauptman PJ. Mode of death from congestive

heart failure: implications for clinical management. Am J Ger Cardiol 2004;13:299-306. 34. Kutner J, Goodlin SJ, Connor SR, Ryndes T, Houser J, Hauptman PJ. Hospice care for

heart failure patients. J Pain Sympt Management 2005;29:525-8. 35. Al-Aly Z, Abbas S, Moore E, Diallo O, Hauptman PJ, Bastani B. The natural history of

renal function following orthotopic heart transplantation. Clin Transplant 2005;19:683-9. 36. Grady KL, Naftel D, Pamboukian SV, Frazier OH, Hauptman PJ, Herre J, Eisen H, Smart

F, Bourge R. Post-operative obesity and cachexia are risk factors for morbidity and mortality after heart transplant: multi institutional study of post-operative weight change. J Heart Lung Transplant 2005:24:1424-30.

37. Hauptman PJ, Zimmer C, Udelson J, Shoaf SE, Mallikaarjun S, Bramer SL, Orlandi C.

Comparison of two doses and dosing regimens of tolvaptan in congestive heart failure. J Cardiovasc Pharmacol 2005;46:609-14.

38. Hauptman PJ, Rector TS, Wentworth D, Kubo S. Quality of life in advanced heart failure:

role of mitral regurgitation. Am Heart J 2006;151:213-18. 39. Packer M, Abraham WT, Mehra MR, Yancy CW, Lawless CE, Mitchell JE, Bijou R,

O’Connor CM, Massie BM, Pina IL, Greenberg BH, Young JB, Fishbein DP, Hauptman PJ, Bourge RC, Strobeck JE, Murali S, Schocken D, Teerlink JR, Levy WC, Trupp RJ, Silver MA. Utility of impedence cardiography for the identification of short-term risk of clinical decompensation in stable patients with heart failure. J Am Coll Cardiol 2006;47:2245-52.

40. Hussain Z, Swindle J, Hauptman PJ. Digoxin use and digoxin toxicity in the post-DIG

Trial era. J Cardiac Fail 2006;12:343-6. 41. Hauptman PJ, Mikolajczak P, Mohr CJ, George A, Hoover R, Swindle J, Schnitzler M.

Chronic continuous home inotropic therapy in end-stage heart failure. Am Heart J 2006;152:1096.e1-1096.e8. NIHMS169492

42. Hauptman PJ, Schnitzler M, Swindle J, Burroughs T. Use of nesiritide before and after

publications suggesting drug-related risks in patients with acute decompensated heart failure. JAMA 2006;296:1876-83. NIHMSID169387

43. Hauptman PJ, Goodlin SJ, Lopatin R, Costanzo MR, Fonarow GC, Yancy CW.


Characteristics of patients hospitalized with acute decompensated heart failure who are referred for hospice care. Arch Int Med 2007;167:1990-7.

44. Hauptman PJ, Swindle J, Hussain Z, Burroughs TE. Physician attitudes toward end-stage

heart failure: results of a national survey. Am J Med 2008;121:127-35. NIHMS169498 45. Lentine KL, Schnitzler MA, Brennan DC, Snyder JJ, Hauptman PJ, Abbott KC, Axelrod

D, Salvalaggio P, Kassiske B. Cardiac evaluation before kidney transplantation: a practice patterns analysis in Medicare-insured dialysis patients. Clin J Am Soc Nephrol 2008;3:1115-1124.

46. Hauptman PJ, Swindle J, Burroughs TE, Schnitzler MA. Resource utilization in patients

hospitalized with heart failure: insights from a contemporary national hospital database. Am Heart J 2008;155:978-85. NIHMS169506

47. Swindle J, Burroughs TE, Schnitzler MA, Hauptman PJ. Short term mortality and costs

associated with cardiac device implantation in patients hospitalized with heart failure. Am Heart J 2008;156:322-8. NIHMS169504

48. Udelson JE, Pressler SJ, Sackner-Bernstein J, Ordronneau P, Lucas MA, Hauptman PJ on

behalf of the Investigators. Compliance with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) Trial. J Cardiac Fail 2009;15:385-93.

49. Rosengren A, Hauptman PJ, Olsson L, Wilhelmsen L, Swedberg K. Effects of body size of

youth and subsequent weight gain on risk of atrial fibrillation in men. Eur Heart J 2009;30:1113-20.

50. McDowell D, Hauptman PJ. Implantable defibrillators in heart transplant recipients:

results of a national survey. J Heart Lung Transplant 2009;28:847-50. 51. Lentine KL, Xiao H, Brennan DC, Schnitzler MA, Abbott KC, Villines TC, Axelrod D,

Snyder JJ, Hauptman PJ. The impact of kidney transplantation on heart failure risk varies with candidate body mass index and donor type. Am Heart J 2009;158:972-82

52. Scherrer JF, Chrusciel T, Zeringue A, Garfield LD, Hauptman PJ, Lustman PJ, Freedland

KE, Carney RM, Bucholz KK, Owen R, True WR. Anxiety disorders increase risk for incident myocardial infarction in depressed and nondepressed Veterans Administration patients. Am Heart J 2010;159:772-9.

53. Dunlay SM, Gheorghiade M, Reid KJ, Allen LA, Chan PS, Hauptman PJ, Zannad F,

Maggioni P, Swedberg K, Konstam MA, Spertus JA. Critical elements of clinical follow-up after hospital discharge for heart failure: insights from the EVEREST trial. Eur J Heart Fail 2010;12:367-74.

54. O'Connor CM, Miller AB, Blair JE, Konstam MA, Wedge P, Bahit MC, Carson P, Haass M,


Hauptman PJ, Metra M, Oren RM, Patten R, Piña I, Roth S, Sackner-Bernstein JD, Traver B, Cook T, Gheorghiade M. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: Results from efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) program. Am Heart J 2010;159:841-849.

55. Hauptman PJ, Swindle J, Burroughs T. Underutilization of beta blockers in patients

undergoing implantable cardioverter defibrillator and cardiac resynchronization procedures. Circulation: Cardiovascular Quality and Outcomes 2010;3:204-11.

56. Swindle J, Rich MW, McCann P, Burroughs TE, Hauptman PJ. Implantable cardiac device procedures in older patients: use and in-hospital outcomes. Arch Int Med 2010;170:631-37. 57. Scherrer JF, Garfield LD, Lustman PJ, Hauptman PJ, Chrusciel T, Zeringue A, Carney

RM, Freedland KE, Bucholz KK, Owen R, Newcomer JW, True WR. Antidepressant utilization is associated with reduced risk for incident myocardial infarction and mortality in depressed patients. Am J Med 2011;124:318-24.

58. Lentine K, Villines T, Xiao H, Schnitzler M, Brennan D, Abbott K, Hauptman PJ.

Cardioprotective medication use after acute myocardial infarction in kidney transplant recipients. Transplantation 2011; 91:1120-6.

59. Allen LA, Gheorghiade M, Reid KJ, Dunlay SM, Chan PS, Hauptman PJ, Zannad F,

Konstam MA, Spertus JA. Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circ Cardiovasc Qual Outcomes 2011;4:389-98

60. Scherrer JF, Garfield LD, Chrusciel T, Hauptman PJ, Carney RM, Freedland KE, Owen R,

True WR, Lustman PJ. Increased risk of myocardial infarction in depressed patients with type 2 diabetes. Diabetes Care 2011;34:1729-34.

61. Udelson JE, Bilsker M, Hauptman PJ, Sequeira R, Thomas I, O’Brien T, Zimmer C,

Orlandi C, Konstam MA. A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction. J Cardiac Fail 2011;17:973-81.

62. Scherrer JF, Chrusciel T, Garfield LD, Freedland KE, Carney RM, Hauptman PJ, Bucholz

KK, Owen R, Lustman PJ. Insufficient treatment, treatment resistant depression and all cause mortality following acute myocardial infarction. Brit J Psychiatry 2012;200:1-6.

63. Teerlink JR, Iragui VJ, Mohr JP, Carson PE, Hauptman PJ, Lovett DH, Miller A, Piña IL,

Thomsom S, Varosy PD, Zile M, Cleland JGF, Givertz MM, Metra M et al. The safety of an adenosine A1-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. Drug Safety 2012;35:233-44.

64. Hauptman PJ, Chibnall J, Guild C, Armbrecht E. Patient perceptions, physician

communication and the cardioverter defibrillator. JAMA Intern Med (formerly Arch Int


Med) 2013;173:571-7. doi: 10.1001/jamainternmed.2013.3171. 65. Hauptman PJ, Burnett J, Gheorghiade M, Grinfeld L, Konstam M, Kostic D, Krasa HB,

Maggioni A, Ouyang J, Swedberg K, Zannad F, Zimmer D, Udelson JE on behalf of the EVEREST investigators. Clinical course of patients with hyponatremia and decompensated systolic heart failure and effect of vasopressin receptor antagonism with tolvaptan. J Cardiac Fail 2013;19:390-97.

66. Stolker JM, Patel AY, Lim MJ, Hauptman PJ. Estimating the adoption of transcatheter

aortic valve replacement in the U.S. Clin Card 2013;11:691-97. 67. Garfield LD, Scherrer JF, Hauptman PJ, Freedland KE, Chrusciel T, Carney RM, Lustman

PJ, Newcomer JW, Owen R, Bucholz, KB, True WR. Do anxiety disorders make an independent contribution to incidence of heart failure? PsychoSom Med 2014;76:128-136.

68. Hauptman PJ, Armbrecht ES, Chibnall JT, Guild C, Timm JP, Rich MW. Errata in medical

publications. Am J Med 2014;127:779-85.e1 69. Jain KK, Hauptman PJ, Spertus JA, Kennedy KF, Bateman TM, Jacobson AF, Stolker JM.

Incremental utility of iodine-123 meta-iodobenzylguanidine imaging beyond established heart failure risk models. J Cardiac Fail 2014;20:577-83.

70. Greenberg A, Verbalis J, Amin A, Burst V, Chiodo JA, Chiong J, Dasta J, Friend K

Hauptman PJ, Peri A, Sigal S. Hyponatremia: current treatment practice and outcomes report of the Hyponatremia Registry: an Observational Multicenter International Study.

Kidney International (in press) 71. Vidic A, Chibnall J, Hauptman PJ. Heart Failure is a major contributor to hospital

readmission penalties. J Cardiac Fail 2015;21:134-137. Consensus Statements / Guidelines 1. Goodlin SJ, Hauptman PJ, Arnold R, Grady K, Hershberger RE, Kutner J, Masoudi F,

Spertus J, Dracup K, Cleary JF, Medak R, Crispell K, Pina I, Stuart B, Whitney C, Rector T, Teno J, Renlund DG. Consensus Statement: Palliative and Supportive Care in Advanced Heart Failure. J Cardiac Failure 2004;10:200-209.

2. Hauptman PJ, Rich MW, Heidenreich PA, Chin J, Cummings N, Dunlap ME, Edwards

ML, O’Connor CM, Gregory D, Pezzella SM, Philbin E. The Heart Failure Clinic: a Consensus Statement of the Heart Failure Society of America. J Cardiac Fail 2008;14:801-15.

3. Allen LA, Grady KL, Stevenson LW, Arnold RM, Cook NR, Felker GM, Francis GS,

Goldstein NE, Hauptman PJ, Havranek EP, Krumholz HM, Mancini D, Matlock DD, Riegel B, Spertus JA. On behalf of the American Heart Association, Council on Cardiovascular Nursing, Council on Clinical Cardiology and the Council on Quality of Care and Outcomes Research. Decision Making in Advanced Heart Failure. A Scientific Statement from the American Heart Association. Circulation 2012;125:1928-1952.


Methods / Clinical Trial Design 1. Hauptman PJ, Pressler SJ, Sackner-Bernstein J, Ordronneau P, Udelson J. Background and

Design of the Prospective Randomized Controlled Assessment of Once-Daily Controlled Release COREG-CR versus Twice-Daily COREG Immediate Release (IR) on Measures of Compliance and Quality of Life in Patients with Heart Failure and Left Ventricular Systolic Dysfunction: the CASPER Trial. Am J Cardiol 2006;98(supplement-1):60-66.

2. Hauptman PJ, Schwartz PJ, Gold M, Borggreffe M, Van Veldhuisen DJ, Starling RC,

Mann D. Rationale and study design of the INcrease Of Vagal TonE in Heart Failure Study: INOVATE-HF. Am Heart J 2012;163:954-962.e1

3. Hauptman PJ, Greenberg A, Verbalis JG, Amin A, Sigal S, Chiong J, Chase S, Dasta J.

Design of a prospective, observational multinational registry to evaluate management and outcomes in patients hospitalized with euvolemic or hypervolemic hyponatremia: The HN Registry. J Clin Trials 2013;5:93-100. DOI: http://dx.doi.org/10.2147/OAJCT.S49421

4. Hauptman PJ, Gottlieb SS. Clinical trial design in contemporary device studies in heart

failure. J Cardiac Fail 2014;20:223-228. Special Articles / Editorials 1. Hauptman PJ, Ting HH, Stone PH. Transplant associated coronary artery disease: from

chronic disease to acute myocardial infarction (editorial). Ann Emerg Med 1995;25:545-547.

2. Hauptman PJ, O’Connor K. Medical Progress: Procurement and allocation of solid organs

for transplantation. N Engl J Med 1997;336:422-31. 3. Hauptman PJ, al-Kaade S. Health related quality of life measurement in heart failure:

challenges for the new millennium. J Cardiac Failure 2001;7:194-201. 4. Hedrich O, Jacob M, Hauptman PJ. Progression of coronary artery disease in non-ischemic

dilated cardiomyopathy. Coronary Artery Disease 2004;15:291-7 5. Hauptman PJ, Burroughs TE. Anything does not go: defining and refining interventions

designed to improve quality in cardiovascular diseases (editorial). Am J Med 2004;117:433-35.

6. Hauptman PJ, Bednarek H. The business concept of leader pricing as applied to heart

failure disease management. J of Disease Management 2004;7:226-34. 7. Hauptman PJ. Measurement of end points in heart failure trials: jousting at windmills?

Mount Sinai J Med 2004;71:298-304. 8. Hauptman PJ, Mehra M. It is time to stop ignoring malignancy in heart transplantation: a

call to arms. J Heart Lung Transplant 2005;24:1111-3.


9. Hauptman PJ, Havranek E. Integrating palliative care into heart failure care. Arch Int Med 2005;165:374-8.

10. Hauptman PJ. Palliation in heart failure: When less and more are more. Am J Hosp

Palliative Med 2006;23:150-2. 11. Hauptman PJ, Sabbah H. Reversal of ventricular remodeling: important to establish and

difficult to define. Eur J Heart Fail 2007;9:325-28. 12. Braunschweig F, Hauptman PJ. Cardiac resynchronization therapy in the intensive care

setting: the promise and peril of using implantable devices off label (editorial). Eur J Heart Fail 2008;10:220-1.

13. Olshansky B, Sabbah N, Hauptman PJ, Colucci WS. The parasympathetic nervous system

and heart failure: pathophysiology and implications for therapy. Circulation 2008;118:863-71.

14. Hauptman PJ. Does it matter why and how patients with heart failure die? A debate that

lives on (editorial). Circulation-Heart Failure 2008;1:89-90. 15. Hauptman PJ. All clinical trials are not created equal: the dilemma of HEAAL (editorial).

Eur J Heart Fail 2008;10:817-8. 16. Ferreira S, Hauptman PJ. Implantation of cardiac defibrillators for primary prevention: a

pendulum too far? (editorial). Expert Rev Cardiovasc Ther 2008;6:1047-50. 17. Hauptman PJ, Mann DL. The Vagus nerve and autonomic imbalance in heart failure: past, present and future. Heart Fail Rev 2011;16:97-99. 18. Cutro R, Rich M, Hauptman PJ. Appropriate use of device therapy in patients of advanced

age: is it too much too late? Int J Cardiol 2012;1:52-55. 19. Hauptman PJ. Medical therapy in the era of implantable cardioverter defibrillators: we

know what to do but are we doing it? Arch Int Med 2012;172:67-68. 20. Januzzi JL, Hauptman PJ. Reversed reverse remodeling: can biomonitoring solve the

clinical conundrum of the 3 R’s? Circulation: Heart Fail 2014;7:388-90. 21. Kirkpatrick JN, Hauptman PJ, Goodlin SJ. Bundling informed consent and advance

planning in chronic cardiovascular disease: we need to talk. JAMA Intern Med 2015;175(1):5-6. doi:10.1001/jamainternmed.2014.6219

22. Hauptman PJ. Addressing disparities in heart failure care without borders. Eur J Heart Fail

2015 (in press) Reviews 1. Hauptman PJ, Cosico J, Halperin J. Dextrocardia. Heart Lung 1992;21:192-5.


2. Hauptman PJ, Gass A, Goldman ME. The role of echocardiography in cardiac

transplantation. J Am Soc Echocardiogr 1993;6:496-509. 3. Hauptman PJ, Nakagawa T, Tanaka H, Libby P. Acute rejection: culprit or coincidence in

the pathogenesis of cardiac graft vascular disease? J Heart Lung Transplant 1995;14(part 2):S173-S180.

4. Bates DW, Miller E, Bernstein SJ, Hauptman PJ, Leape LL. Coronary angiography and

angioplasty after acute myocardial infarction: a literature review. Ann Int Med 1997;126:539-50.

5. Hauptman PJ, Mudge GH Jr. Evaluation and management of potential heart donors for

transplantation. Cardiology in Review 1998;6:100-06. 6. Hauptman PJ, Kelly R. Cardiovascular drugs: digitalis. Circulation 1999;99:1265-70. 7. Hauptman PJ, Kelly R. Cardiac glycosides in the next millenium. Prog Cardiovasc Dis

1999;41:247-54. 8. Betkowski AS, Hauptman PJ. Update on recent clinical trials in congestive heart failure.

Curr Opin Cardiol 2000;15:293-303. 9. Hauptman PJ. Medication adherence in heart failure. Heart Fail Rev 2008;13;99-106. 10. Rosengren A, Hauptman PJ. Women, men and heart failure- a review (invited). Heart

Failure Monitor 2008;6:34-40. 11. Neumayr R, Hauptman PJ. Beta adrenergic receptor blockers and the risk of heart failure

following acute myocardial infarction: a critical review. Current Heart Failure Reports 2009;6:220-28.

12. Lentine KL, Hurst FP, Jindal RM, Villines TC, Kunz JS, Yuan CM, Hauptman PJ, Abbott KC. Cardiovascular risk assessment among potential kidney transplant candidates: approaches and controversies. Am J Kidney Dis 2010; 55:152-67

13. Desai MY, Watanabe M, Laddu A, Hauptman PJ. Pharmacologic modulation of vagus

nerve activity in heart failure. Heart Fail Rev 2011;16:179-93. 14. Hauptman PJ. The clinical challenge of hyponatremia in heart failure. J Hospital Med

2012;7:S6-S10 15. McCann P, Hauptman PJ. Inotropic therapy: an important role in the treatment of

advanced symptomatic heart failure. Med Clin North Am 2012;96:943-54 Guest Editorship 1. Hauptman PJ. The Vagus Nerve and Heart Failure. In: Heart Failure Reviews 2011,


volume 16, issue 2. Chapters in Books 1. Hauptman PJ and Kelly RA. Digitalis Glycosides. In: Hosenpud JD and Greenberg BH,

eds. Congestive Heart Failure: Pathophysiology, Diagnosis and Comprehensive Approach to Therapy. 2nd edition. Philadelphia: Lippincott Williams & Wilkins, 2000. Revision in 3rd edition, published Aug-2006. Reviewed in: NEJM 2007;356:2227

2. Hauptman PJ. Management of Long-Term Survivors of Heart Transplantation. In:

Braunwald E, ed. Harrison’s Online. McGraw Hill 2001. 3. Hauptman PJ, Mikolajcak P. Palliative and Hospice Care in Heart Failure. In: Yancy C,

Young JB, eds. Therapeutic Strategies in Heart Failure. 1st edition. Oxford: Clinical Publishing/Oxford Medical Publishing Ltd, 2007

4. Hauptman PJ, Swedberg K. Management of Overt Heart Failure. In: Yusuf S, Cairns J,

Camm J, Fallen E, Gersh B, eds. Evidence-Based Cardiology, 3rd edition. Oxford: Blackwell Publishing 2009

5. Hauptman PJ, McCann P. Inotropic Therapy for Heart Failure: Past, Present and Future.

In: Deedwania P, Mather P, eds. Drug and Device Therapy in Heart Failure, 1st edition. Jaypee Brothers Medical Publishing 2014

Other Publications, peer reviewed 1. Hauptman PJ, Raza M. Electrocardiographic artifact with a transcutaneous electrical nerve

stimulation unit. Int J Cardiology 1992;34:110-12. 2. Hauptman PJ, Gass A, Cohen M, Goldman ME, Israel D, Ambrose JA. Endomyocardial

biopsy: Advantages of adding a posterior bend to the bioptome. Cathet Cardiovasc Diag 1992;27:228-9.

3. Hauptman PJ, Mechanick J, Lansman S, Gass A. Fatal hyperthyroidism after amiodarone

treatment in a cardiac transplant recipient. J Heart Lung Transplant 1993;12:513-16. 4. Hauptman PJ, Body S, Fox J, Couper GS, Loh E. Implantation of a pulsatile external left

ventricular assist device: role of intraoperative transesophageal echocardiography. J Cardiothorac Vasc Anesth 1994;8:340-41.

5. Hauptman PJ, Selwyn AP, Cooper CJ. Use of the left internal jugular vein approach in

endomyocardial biopsy. Cathet Cardiovasc Diagn 1994;32:42-43. 6. Alhadab T, Alvarez F, Phillips NJ, Hauptman PJ. Malignant fibrous histiocytoma of the

lung presenting as bronchial obstruction in a heart transplant recipient. J Heart Lung Transplant 2002;21:1140-43.

7. Bhalodia R, Cortese C, Graham MA, Hauptman PJ. Fulminant acute cellular rejection with

negative findings on endomyocardial biopsy. J Heart Lung Transplant 2006;25:989-92.


8. Piotrowski BD, Armbrecht ES, Hauptman PJ. Social milestones in heart transplantation. J

Heart Lung Transplant 2010;29:1204-5 9. Cyr PL, Slawsky KA, Olchanski N, Krasa H, Goss TF, Zimmer C, Hauptman PJ. Effect of

serum sodium and tolvaptan use on length of stay in patients hospitalized for heart failure. Am J Health-Syst Pharm 2011;68:328-33.

10. Vidic A, McCann P, Romero Ramirez JM, Hauptman PJ. Extreme reverse remodeling in a

patient with dilated cardiomyopathy. Circulation: Heart Fail 2014;7:1063-65. 11. Mikolajczak P, Aziz Z, Hauptman PJ. Challenges in Clinical Electrocardiography: a case

of possible pacemaker undersensing. JAMA Int Medicine, published online March 09, 2015. doi:10.1001/jamainternmed.2015.0174

12. Hirst C, Jureidini S, Hauptman PJ. Arrhythmias in a long-term adult survivor with

uncorrected Tetralogy of Fallot: case report and review of the literature. J Electrocardiology (in press)

Book Reviews 1. Hauptman PJ. Mechanical circulatory support therapy in advanced heart failure, Au: Deng

M and NakaY, ISBN 9781860947735. Eur J Heart Fail 2007;9:1140. Research Letters 1. Hauptman PJ, Feinberg MB. Occupational exposure to HIV among house staff. N Engl J

Med 1990;323:1356. 2. Moinuddin M, Hauptman PJ. Limitations of listing criteria for heart transplantation in the

U.S.: Call for a critical review. J Heart Lung Transplant 2004;23:1123. 3. Hauptman PJ, McCann P, Ramirez Romero JM, Mayo MM. Reference laboratory values

for digoxin following publication of DIG trial data: research letter. JAMA Internal Medicine 2013;173:1552-4.

Letters 1. Hauptman PJ. HLA compatibility. N Engl J Med 1994; 331:404. 2. Chheda M, Hauptman PJ. Cardiopulmonary resuscitation on television. N Engl J Med

1996;335:1606. 3. Hauptman PJ. Cardiogenic shock. Lancet 2000;356:1687. 4. Hauptman PJ. REMATCH trial. N Engl J Med 2002;346:1023. 5. Hauptman PJ. Response to Case 15-2009. A 25-year old man with coma after cardiac

arrest. N Engl J Med 2009;361;7:724.


Editor’s Page commentary 1. Hauptman PJ. New editors, same dedication to excellence. J Card Fail 2015;21:1 2. Hauptman PJ. An April potpourri: mini-focus issues, brief reports, podcasts, biomarkers,

cognition and more. J Card Fail 2015;21:261-2. 3. Hauptman PJ. The readmissions obsession and magical numbers. J Card Fail 2015;21:365-

6. 4. Hauptman PJ. Do we have consensus about consensus statements? J Card Fail 2015 (in

press) Other Publications, educational 1. Hauptman PJ. Palliative care in end-stage heart disease. The ACCF Self Assessment

Program-8; access at www.cardiosource.org (2012). Other Media, non peer reviewed 1. Hauptman PJ. The Odyssey. Cardiology blog at www.eCardiologyNews.com. April 2012-

September 2014 Abstracts 1. Merino A, Hauptman PJ, Badimon L, Badimon JJ, Goldman ME. Echogenic smoke is shear

rate dependent. Circulation 1991;84(II):692. 2. Merino A, Hauptman PJ, Fuster V, Badimon L, Badimon JJ, Goldman ME. Echogenic

smoke is platelet independent. Circulation 1991;84(II):162. 3. Hauptman PJ, Gass A, Fyfe B, Courtney M, Lansman S, Teichholz LE, Ambrose JA, Gorlin

R, Goldman ME. Endomyocardial biopsy causes tricuspid regurgitation after cardiac transplantation. Circulation 1992;86(I):464.

4. Hauptman PJ, Aranki SF, Couper GS, Adams DH, Mudge GH, Loh E. Non-invasive

evaluation of the cardiac donor and early survival following orthotopic cardiac transplantation. Circulation 1993;88(4):I-287.

5. Hauptman PJ, Givertz M, Kartashov AI, Balaschak K, Mudge GH, Colucci WS, Hartley

LH. Predictive value of functional capacity before and after cardiac transplantation. Circulation 1994; 90(4):I-153.

6. Ayanian JZ, Hauptman PJ, Guadagnoli E, Antman EM, Pashos CL, McNeil BJ. Drug

beliefs and practices for myocardial infarction among generalist and specialist physicians. J Gen Intern Med 1994;9(suppl 2):46.

7. Adams DH, Hauptman PJ, Couper GS, Rizzo RJ, Kartashov AI, Balaguer JM, Dekkers R,

McCarthy P, Sullivan TE, Stevenson LW, Aranki SF. Mechanical ventricular support for acute cardiac allograft failure. J Heart Lung Transplant 1995; 14(1) Part II:S89.


8. Davis SF, Kartashov AI, Adams DH, Couper GS, Aranki SF, Stevenson LW, Hauptman PJ. Early acute rejection predicts very late acute rejection following cardiac transplantation. International Meeting on Acute Allograft Rejection, Milan, 1995.

9. Harrigan P, Otis D, Recht A, Gelman R, Hauptman P, Hayes D, Henderson IC, Harris JR,

Shapiro C. The effect of adjuvant radiation therapy on cardiac events in breast cancer patients treated with doxorubicin. Proc Annu Meet Am Soc Clin Oncol 1995;14:A109.

10. Miller L, Kobashigawa J, Hauptman PJ, Valantine H, Ventura H, ODonnell J, Yeung A,

Wiedermann J, Greenwalt T. Definition of critical cyclosporine level for preventing rejection in heart transplant patients. J Heart Lung Transplant 1996;15(1) Part II:S77.

11. Hauptman PJ, OConnor K, Bradley J, Mudge GH, Delmonico F, Dec GW. Allocation of

hearts in New England: potential lessons for national policy. J Heart Lung Transplant 1998;17(1):102.

12. Hauptman PJ, O’Connor K, Delmonico F, Wolf R, McNeil BJ. Coronary angiography in the

evaluation of potential heart donors. Circulation 1998;98(17):I-195. 13. DiSalvo T, Hauptman PJ, Guadagnoli E, Normand SL, Palmer H, McNeil B. Clinical

quality performance measures for cardiovascular diseases. Circulation 1999;100(18):I-530. 14. Hauptman PJ, al-Kaade S, Romeis J. Quality of quality of life data in heart failure trials. J

Cardiac Failure 2000;6:66. 15. DiSalvo TG, Normand SL, Hauptman PJ, Guadagnoli E, Palmer HR, McNeil BJ. Pitfalls in

assessing the quality of ambulatory care for congestive heart failure in managed care plans. J Am Coll Cardiol 2001;37(supplA):512A.

16. Betkowski AS, Graff R, Chen JJ, Hauptman PJ. Panel reactive antibody screening practices

prior to heart transplantation. J Heart Lung Transplant 2001;20:165. 17. Graff R, Betkowski AS, Hauptman PJ. Evaluation of pre-transplant sensitization: a survey

of tissue typing laboratories. J Heart Lung Transplant 2001;20:136. 18. Young JB, Hauptman PJ, Naftel DC, Ewald G, Aaronson K, Dec GW, Taylor DO, Higgins

R, Platt L, Kirklin J. Determinants of early graft failure following cardiac transplantation: a 10-year multi-institutional multivariable analysis. J Heart Lung Transplant 2001;20:185.

19. Hedrich O, Jacob M, Derfler MC, Hauptman PJ. Congestive heart failure disease

management programs: suppliers in the cardiovascular food chain. J Cardiac Failure 2001:7:101

20. Czarnik B, Yip D, Hauptman PJ. Management of long-term heart transplant survivors with

very low cyclosporin levels: a safe approach? Circulation 2001;104(II):646-7. 21. Kirklin JK, Naftel DC, Bourge RC, McGiffin DC, Hill JA, Rodeheffer RJ, Jaski BE,


Hauptman PJ, Weston, M, White-Williams C. Evolving trends in causes of death after heart transplantation: a 10-year multi-institutional study. American Association for Thoracic Surgery, Washington DC, May 2002.

22. Hauptman PJ, Pina I, Jones PG, Spertus J. Short-term changes in standard functional and

quality of life measures among patients with advanced heart failure: The Kansas City Cardiomyopathy Questionnaire Interpretability Study. J Cardiac Failure 2002;8:S68.

23. Hauptman PJ, Wentworth D, Kubo S. Correlates of quality of life in advanced heart failure:

insights from the Acorn trial. J Am Coll Cardiol 2003;41:212A 24. Abbas S, Moore ES, Hauptman PJ, Bastani B. Renal outcome in long-term heart transplant

survivors. J Am Soc Nephrol 2003;14:657A. 25. Hedrich O, Jacob MC, Gavard JA, Hauptman PJ. Progression of coronary artery disease in

non-ischemic dilated cardiomyopathy: an under-estimated phenomenon? J Cardiac Failure 2003;9(5):S99.

26. Derfler MC, Jacob MC, Wolf RE, Hauptman PJ. Death from congestive heart failure:

experience of a disease management program. J Cardiac Failure 2003:9(5):S95. 27. Hauptman PJ. Clinton Redux: It’s the malignancy, stupid! [Aristotle’s Corner Abstract

Presentations]. J Heart Lung Transplant 2004;23:S120-1. 28. George A, Hedrich O, Mikolajczak PC, Hoover R, Gavard JA, Hauptman PJ. Parenteral

home inotropic therapy in heart failure patients: preliminary analysis from a multi-state Medicare cohort. Accepted for presentation at the 5th Annual American Heart Association meeting on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, May 2004, Washington DC.

29. Hauptman PJ, Lo HK, Han C, Cabot CF, Packer M. Physician global assessment of heart

failure patients: comparison with patient global assessment and quality of life scores in the ATTACH Trial. J Cardiac Fail 2004;10:S80.

30. Czarnik B, Taschner B, Kuehn SC, Wolf RE, Hauptman PJ. Lack of correlation between

levels of BNP and responses on a visual analog scale in decompensated heart failure: potential implications for clinical trial design. J Cardiac Fail 2004;10:S105.

31. Hauptman PJ, Goodlin SJ, Costanzo MR, Lopatin M. The sickest of the sick in the

ADHERE Registry: characteristics of patients hospitalized with acute decompensated heart failure who are referred for hospice care. J Cardiac Fail 2004;10:S117.

32. Mikolajczak P, George A, Oliver D, Hoover R, Hedrich O, Hauptman PJ. Preliminary

economic analysis of chronic continuous home inotropic therapy in end-stage heart failure: insights from a multi-state Medicare database. J Cardiac Fail 2004;10:S109

33. Hare JM, Perrone S, Eisen H, McCurry K, Hauptman P, Simonsen S, Crespo M, Arizon J,


Kobashigawa J, Jarcho J. Everolimus in de novo cardiac transplant recipients: 48-month follow-up. J Heart Lung Transplant 2005;24:S61.

34. Hauptman PJ, Burroughs TE, Swindle J, Jans M, Biener L. Physician attitudes and beliefs

regarding the care of patients with end-stage heart failure: insights from a national pilot study. J Cardiac Fail 2005;11:S169.

35. Hauptman PJ, Hussain ZM. Patterns of digoxin use and digoxin toxicity in the post-DIG

trial era. J Cardiac Fail 2005;11:S165. 36. Schnitzler M, Hauptman PJ, Takemoto SK, Burroughs TE, Salvalaggio P, Lentine K, Lee R,

Feurer I, Zavala E. Benefit from reallocation to status 1 from 2 in heart transplantation. World Transplant Congress annual meeting, Boston MA July 2006.

37. Schnitzler M, Hauptman PJ, Takemoto SK, Burroughs TE, Salvalaggio P, Lentine K, Lee R,

Feurer I, Zavala E. The impact of cold ischemia time on the life-year benefit of heart transplant. World Transplant Congress annual meeting, Boston MA July 2006

38. Hauptman PJ, Swindle J, Schnitzler MA, Burroughs T. Rapid de-adoption of nesiritide

following adverse publicity: insights from a large national hospital database. J Cardiac Fail 2006;12:S96.

39. Swindle J, Schnitzler MA, Hussain Z, Takemoto S, Burroughs T, Hauptman PJ.

Biventricular pacemaker placement in clinical practice: insights from a managed care organization database. J Cardiac Fail 2006;12:S108.

40. Hussain Z, Burroughs T, Hauptman PJ. Lack of uniformity in safety reporting for CRT

implantation in randomized clinical trials and pre market approval applications. J Cardiac Fail 2006;12:S93.

41. Zahra MS, Srun SW, Wood EG, Belsha CW, Marshall DL, Hauptman PJ, Schowengerdt

KO, Balfour IC. Medium term renal outcome of pediatric heart transplant patients on reduced calcineurin inhibitor and rapamycin. J Heart Lung Transplant 2007;26:S246.

42. Schnitzler MA, Buchanan PM, Swindle J, Lee R, Hauptman PJ. The cost-effectiveness of

increasing the supply of hearts for transplant. J Heart Lung Transplant 2007;26:S63. 43. Schnitzler MA, Buchanan PM, Burroughs TE, Lee R, Hauptman PJ. Impact of ischemia

time on the outcomes of heart transplant. J Heart Lung Transplant 2007;26:S64. 44. Higgins RS, Edwards LL, Okum EJ, Mullen M, Dunlap SH, Hauptman PJ, Pagani FD,

Aaronson KD. Current status of heart transplantation as therapy for advanced heart failure in African Americans. J Heart Lung Transplant 2007;26:S75.

45. Swindle J, Schnitzler M, Burroughs T, Hauptman PJ. Heterogeneity of resource utilization

in hospitalized patients with heart failure. 8th American Heart Association Scientific Forum on Quality of Care and Outcomes Research, May 2007.


46. Udelson JE, Pressler SJ, Sackner-Bernstein J, Lukas MA, Ordronneau PA, Massaro J,

Hauptman PJ. Compliance with once daily controlled release vs. twice daily immediate release carvedilol in patients with heart failure: the CASPER trial. J Cardiac Fail 2007;13:S135.

47. Swindle J, Schnitzler M, Burroughs T, Hauptman PJ. The highest cost heart failure

hospitalizations: insights from a national hospital database. J Cardiac Fail 2007;13:S167. 48. Hauptman PJ, Swindle J, Schnitzler M, Burroughs T. High short term mortality and cost

associated with device implantation in hospitalized heart failure patients receiving inotropic therapy. J Cardiac Fail 2007;13:S158-9.

49. O’Connor C, Miller A, Konstam M, Carson P, Haass M, Hauptman PJ, Pena I, Metra M,

Sackner-Bernstein J, Gheorghiade M. Mode of death and cardiovascular rehospitalization in patients admitted with acute heart failure: results from the EVEREST program. Eur J Heart Fail 2008;7:S59-60.

50. Lentine KL, Xiao H, Schnitzler MA, Hauptman PJ. Heart failure risk before and after

kidney transplantation: importance of body mass index. J Cardiac Fail 2008;14:S83. 51. Hauptman PJ, Swindle J, Burroughs T. Underutilization of evidence-based medication in

patients undergoing cardiac device procedures: hardware over pills? J Cardiac Fail 2008;14:S93

52. Allen LA, Reid KJ, Dunlay SM, Chan PS, Hauptman PJ, Kosiborod M, Konstam MA,

Swedberg K, Zannad F, Maggioni AP, Blair JE, Gheorghiade M, Spertus JA. Identifying patients hospitalized with heart failure at high risk for poor future health status. AHA Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference 2009

53. Swindle J, Rich MW, McCann P, Hauptman PJ. Implantable device therapy in

octogenarians and nonagenarians: insights from a national hospital database. J Cardiac Fail 2009;15:S104

54. Swindle J, Rich MW, Hauptman PJ. In-hospital mortality associated with device

implantation: influence of age and procedural complications. J Cardiac Fail 2009;15:S91 55. Cyr PL, Slawsky K, Olchanski N, Krasa H, Zimmer C, Ouyang J, Goss TF, Udelson J,

Hauptman PJ. Effect of tolvaptan on hospital length of stay in hyponatremic patients hospitalized for heart failure. 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, October 2009.

56. Cyr PL, Slawsky K, Olchanski N, Krasa H, Zimmer C, Ouyang J, Goss TF, Udelson J,

Hauptman PJ. Evaluation of the association between serum sodium and length of stay in patients hospitalized for heart failure. 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, October 2009.


57. Armbrecht ES, Behera A, Hauptman PJ. Regional, gender and racial variance in utilization

of implantable cardiac devices. AHA Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, May 2010, Washington DC.

58. Armbrecht ES, Hauptman PJ. Trends in heart failure epidemiology in a midwestern state:

ruralness and race over a twelve year period. J Cardiac Fail 2010;16:S77. 59. Chiong J, Hauptman PJ, Kim S. Hyponatremia in hospitalized heart failure patients: interim

data from an observational, prospective, multi-center, global registry. J Cardiac Fail 2011:17:S100.

60. Hauptman PJ, Chibnall J, Guild G, Armbrecht E. Patient perception of physician-patient

communication at time of implantable defibrillator implant decision. J Cardiac Fail 2012;18:S91.

61. Chiong J, Hauptman PJ, Chiodo J. Hospital management of hyponatremia in patients with

heart failure: interim data from a multi-center registry. J Cardiac Fail 2012;18:S94. 62. Patel AY, Lim MJ, Hauptman PJ, Stolker JM. Anticipated utilization of transcatheter aortic

valve replacement reflects cautious optimism of the U.S. interventional community (TCT 816). J Am Coll Cardiol 2012;60(17):B237

63. Hauptman PJ, McCann P, Ramirez Romero JM, Mayo MM. Reference laboratory values for

digoxin following publication of DIG trial data. J Cardiac Fail 2013;19:S84 64. Chiong JR, Hauptman PJ, Dunlap ME, Chiodo J, Chase SL. Hospital management of

hyponatremia in patients with heart failure: final report from the HN Registry. J Cardiac Fail 2014;20:8S:S62-3

65. Hauptman PJ, Ward S, Blume SW. Digoxin toxicity: insights from 24,547 cases. J Cardiac

Fail 2014;20:8S:S48 66. Hauptman PJ, Vidic A, Chibnall JT. Contributors to hospital readmission penalties. J

Cardiac Fail 2014;20:8S:S48 67. Sadhu JS, Sadhu EM, Hauptman PJ, Rich MW. Resuscitation preferences of older patients

hospitalized with heart failure: temporal trends and associations with patient and hospital factors. To be presented at QCOR 2015, Baltimore MD

In submission or revision 1. Vidic A, Chibnall J, Goparaju N, Hauptman PJ. Subgroup analyses of randomized clinical

trials in heart failure: a critical appraisal. Am J Cardiol (in submission) 2. Dunlap ME, Hauptman PJ, Amin AN, Chase SL, Chiodo JA, Chiong JR, Dasta JF. Current

management of hyponatremia in acute HF: a report from the Hyponatremia Registry. JACC Heart Fail (in submission)

CURRICULUM VITAE Paul J. Hauptman, M.D.s3.amazonaws.com/.../CV_Paul_Hauptman_MD.pdf · CURRICULUM...

Documents

Transcript of CURRICULUM VITAE Paul J. Hauptman, M.D.s3.amazonaws.com/.../CV_Paul_Hauptman_MD.pdf · CURRICULUM...